Context: Delirium impedes communication and contributes to symptom distress in patients with advanced cancer. There are few prospective data on the reversal of delirium in this population.
Objectives: To evaluate the occurrence, precipitating factors, and reversibility of delirium in patients with advanced cancer.
Design: Prospective serial assessment in a consecutive cohort of 113 patients with advanced cancer. Precipitating factors were examined using standardized criteria; 104 patients met eligibility criteria.
Setting: Acute palliative care unit in a university-affiliated teaching hospital.
Main Outcome Measures: Delirium occurrence and reversal rates, duration, and patient survival. Strengths of association of various precipitating factors with reversal were expressed as hazard ratios (HRs) in univariate and multivariate analyses.
Results: On admission, delirium was diagnosed in 44 patients (42%), and of the remaining 60, delirium developed in 27 (45%). Reversal of delirium occurred in 46 (49%) of 94 episodes in 71 patients. Terminal delirium occurred in 46 (88%) of the 52 deaths. In univariate analysis, psychoactive medications, predominantly opioids (HR, 8.85; 95% confidence interval [CI], 2.13-36.74), and dehydration (HR, 2.35; 95% CI, 1.20-4.62) were associated with reversibility. Hypoxic encephalopathy (HR, 0.39; 95% CI, 0.19-0.80) and metabolic factors (HR, 0.44; 95% CI, 0.21-0.91) were associated with nonreversibility. In mulitivariate analysis, psychoactive medications (HR, 6.65; 95% CI, 1.49-29.62), hypoxic encephalopathy (HR, 0.32; 95% CI, 0.15-0.70), and nonrespiratory infection (HR, 0.23; 95% CI, 0.08-0.64) had independent associations. Patients with delirium had poorer survival rates than controls (P<.001).
Conclusions: Delirium is a frequent, multifactorial complication in advanced cancer. Despite its terminal presentation in most patients, delirium is reversible in approximately 50% of episodes. Delirium precipitated by opioids and other psychoactive medications and dehydration is frequently reversible with change of opioid or dose reduction, discontinuation of unnecessary psychoactive medication, or hydration, respectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinte.160.6.786 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pegloticase and Methotrexate Cotherapy in Patients With Uncontrolled Gout With Prior Pegloticase Monotherapy Failure: Findings of an Open-Label Trial.
ACR Open Rheumatol
January 2025
Amgen, Inc (formerly Horizon Therapeutics plc), Deerfield, Illinois.
Objective: Patients with uncontrolled gout have few treatment options. Pegloticase lowers serum urate (SU) levels, but antidrug antibodies limit SU-lowering response and increase infusion reaction (IR) risk. Methotrexate (MTX) cotherapy increases pegloticase response rates and lowers IR risk in pegloticase-naïve patients.
View Article and Find Full Text PDFGut Microbiota Alterations in Patients With Kawasaki Disease.
Arterioscler Thromb Vasc Biol
January 2025
Department of Pediatrics, Division of Pediatric Infectious Diseases, Guerin Children's, Cedars-Sinai Medical Center, Los Angeles, CA.(P.K.J., M.A., M.N.R.).
The intestinal microbiota influences many host biological processes, including metabolism, intestinal barrier functions, and immune responses in the gut and distant organs. Alterations in its composition have been associated with the development of inflammatory disorders and cardiovascular diseases, including Kawasaki disease (KD). KD is an acute pediatric vasculitis of unknown etiology and the leading cause of acquired heart disease in children in the United States.
View Article and Find Full Text PDFOncological Feasibility of Limited Neck Dissection in cN0 Supraglottic Laryngeal Cancer.
Head Neck
January 2025
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Background: Supraglottic squamous cell carcinoma (SCC) is a significant portion of head and neck cancers, with the management of clinically negative necks (cN0) through selective neck dissection (SND) being debated due to potential morbidities and low metastasis rates in levels IIb and IV.
Methods: This study is a retrospective, multicenter examination of the potential feasibility of limited neck dissection (LND), including only levels IIa and III in cN0 supraglottic SCC patients. It analyzed occult metastasis rates and explored relapse occurrences alongside potential predictors of lymph node metastasis.
[ORL : what's new in 2024].
Rev Med Suisse
January 2025
Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, Centre hospitalier universitaire vaudois, 1011 Lausanne.
This article highlights recent advancements in otorhinolaryngology. It reviews innovations in managing sudden sensory-neural hearing loss through low-dose glucocorticoid treatments and explores pediatric audiology breakthroughs, particularly gene therapy for DFNB9 deafness. In speech pathology and oncology, a new minimally invasive robotic surgical approach enhances organ preservation for head and neck cancers.
View Article and Find Full Text PDF[Cardiology. Rhythmology, hypertension, dyslipidemia and aortic diseases].
Rev Med Suisse
January 2025
Service de cardiologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Atrial fibrillation (AF) is common and its treatment is complex. The new European guidelines emphasize a patient-centered approach, considering the risk factors that contribute to AF and their management in primary and secondary prevention. Recent advances in electrophysiology include the development of new ablation techniques and the implantation of a leadless bicameral pacemaker.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!